ARC Centre for Electrochemicals Science in collaboration with researchers from the University of Texas at Dallas, have developed novel graphene fibres as a new electrical stimulation device that could replace the use of pharmaceuticals to treat a range of medical conditions. For more information see the IDTechEx report on Bioelectronic Medicine 2019-2029.
While pharmaceutical drugs have revolutionized the treatment of a multitude of conditions, there are a number of limitations in terms of side effects and focused delivery. The emerging field of electroceuticals allows for the localized targeting of electrical stimulation to the neural circuits of specific tissues and organs to develop, improve and regenerate performance.
Up until recently, implantable electrodes for electroceuticals were created using standard materials, which resulted in some compatibility issues with soft tissue, therefore limiting the effectiveness of the electrical communication with the nerve.
To combat this challenge, the ACES team used the traditional wet spinning fabrication method to manufacture a new style of fibre based on graphene to develop the ‘sutrode’, which combines the electrical properties of an electrode with the mechanical properties of a suture.
Read the full article here:
About the National Graphene Association (NGA)
The National Graphene Association is the main organization and body in the U.S. advocating and promoting the commercialization of graphene. NGA is focused on addressing critical issues such as policy and standards development that will result in effective integration of graphene and graphene based materials globally. NGA brings together current and future graphene stakeholders — entrepreneurs, companies, researchers, developers and suppliers, investors, venture capitalists and government agencies — to drive innovation, and to promote and facilitate the commercialization of graphene products and technologies.